Nathan Hale, DO
Urology · Charleston, WVNPI 1861719650
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 47.9% of the total. Reporting peaked in 2024 at $4,313 and has fallen 81.7% since, to $789 in 2025.
Across 125 payments — averaging $54.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Boston Scientific$922
- Janssen Scientific Affairs, LLC$279
- Astellas Pharma US Inc$255
- Sumitomo Pharma America, Inc.$248
- Urogen Pharma, Inc.$216
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$1853%
- Travel & lodging$1,39020%
- Food & beverage$3,68654%
- Education$1,60723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $3,291 |
| Boston Scientific | 12 | $922 |
| Janssen Scientific Affairs, LLC | 2 | $279 |
| Astellas Pharma US Inc | 9 | $255 |
| Sumitomo Pharma America, Inc. | 11 | $248 |
| Urogen Pharma, Inc. | 8 | $216 |
| Myriad Genetic Laboratories, Inc. | 9 | $175 |
| Myovant Sciences Inc. | 9 | $165 |
| Pfizer | 9 | $154 |
| Merck | 5 | $139 |
| Axonics, Inc. | 3 | $138 |
| Johnson & Johnson(2 entities) | 4 | $130 |
| Bioprotect Medical, Inc. | 1 | $88 |
| Neotract Inc. | 1 | $78 |
| Richard Wolf Medical Instruments Corp. | 1 | $74 |
| Convatec Inc. | 1 | $59 |
| Dendreon Pharmaceuticals LLC | 2 | $57 |
| AbbVie | 3 | $53 |
| Olympus America Inc. | 3 | $53 |
| Blue Earth Diagnostics | 2 | $48 |
| Laborie Medical Technologies Corp. | 1 | $32 |
| Novartis | 1 | $27 |
| Halozyme Inc | 1 | $26 |
| Ambu Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Procept Biorobotics Corporation | 1 | $20 |
| Innocoll Pharmaceuticals Limited | 1 | $19 |
| EDAP Technomed Inc | 1 | $16 |
| Photocure Inc | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$1,500
- Da Vinci Surgical System$1,367
- AMS 700$299
- Erleada$129
- JELMYTO$125
- ORGOVYX$125
- LithoVue$111
- AdVance XP$102
How this compares
$6,868 in reported general payments places this provider in the 85th percentile of 67 urology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 17 | $248,824 |
| MyrbetriqMirabegron | 38 | $32,544 |
| OrgovyxRelugolix | 12 | $30,252 |
| Tamsulosin Hcl | 257 | $2,732 |
| Oxybutynin Chloride ErOxybutynin Chloride | 60 | $1,315 |
| Silodosin | 12 | $869 |
| Finasteride | 68 | $775 |
| Estradiol | 12 | $653 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $350 |
| Oxybutynin Chloride | 30 | $334 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $253 |
| Cephalexin | 100 | $241 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $168 |
| Ciprofloxacin Hcl | 34 | $91 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $255 | $281,36855 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $248 | $30,25212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 67 urology providers in West Virginia.
Other urology in Charleston
- Joshua LohriCharleston$8K
- Samuel DeemCharleston$6K
- James TierneyCharleston$6K
- Michael StencelCharleston$5K
- Ryan FitzwaterCharleston$3K
- Ross OliverCharleston$2K
- Victoria ButcherCharleston$1K
- Hugh SmithCharleston$269
- Jaschar Shakuri-RadMorgantown$77K
- Ali HajiranMorgantown$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.